Access and Disparities in Comprehensive Pain Management for Chronic Low Back Pain

By: Sebastian Spataro, BA and BS Candidate
Mentor: Molly Candon, PhD
Some definitions

**Chronic pain management**
Medications or treatments received to treat chronic pain

**Comprehensive pain management**
Methods used to address chronic pain that deviate from the most common treatment (opioids)

**Chronic pain**
In this study: 2 diagnoses more than 90 days apart.
AKA: Prolonged or constant episodes of pain through a significant amount of time.
Overview and Significance
Chronic pain is an epidemic in the United States.

- Chronic pain is the leading cause of disability worldwide.
- 1 in 5 adults experience chronic pain, and 1 in 10 experience high impact chronic pain.
Chronic pain has huge and multifaceted effects.

- Economic burden of chronic pain are higher than those of heart disease, cancer, and diabetes, combined.
- Chronic pain has multifaceted causes and effects.
- Disparities in outcomes exist.
Overreliance on opioids is a root cause of the epidemic.

- Opioids are used to treat acute pain, given high effectiveness and addictiveness.
- Its prescriptions to treat chronic pain increased addiction of many to opioids, underlying the epidemic.
- Opioid epidemic is another big burden implied by chronic pain.

Safe and effective treatments for chronic pain management are needed!
The opioids to comprehensive pain management transition is not simple.

3 MAIN REASONS

- Health services research around pain management is limited, overwhelmingly focusing on opioids and the gap between white and black patients.
- This transition exacerbates disparities, as 1) chronic pain disproportionately affects minorities and 2) other treatments are less accessible to them.
- Insurance is acknowledged as the principal cause of disparities in comprehensive pain management.
Aims
Disparities in Comprehensive Pain Management

Aim: To examine trends in the utilization of comprehensive chronic low back pain (CLBP) care in the U.S., and how utilization differs across demographic and socioeconomic groups.
Analyzed treatments

Pharmacological treatments
- Muscle relaxers
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Gabapentinoids
- Opioids

Current literature

Non-Pharmacological treatments
- Acupuncture
- Psychotherapy
- Physical Therapy
- Occupational Therapy
- Chiropractor

Our work
Methods
Our approach: Methods highlights

➔ National insurance claims data
  ◆ Optum: hundreds of millions of claims for tens of millions of covered lives
  ◆ Valuable approach: income drives pain management.
    ● Non-opioid medications and/or treatments are expensive
    ● Hassle costs in non-pharmacological care
    ● Income and health literacy

➔ Ability to associate each claim with a wide range of sociodemographic variables. Some examples:
  ◆ Education
  ◆ Race
  ◆ Income
  ◆ Parenthood
  ◆ Others
Findings & Next Steps
Main findings

❖ Pharmacological
  ➢ Black and Hispanic patients were more likely to receive Muscle Relaxers, Gabapentin, NSAIDs
  ➢ After adjusting, relationships remained, but OR coefficient decreased in magnitude

❖ Opioids
  ➢ Order of likelihood: Black, White, Hispanic, Asian
    ■ Adjusted and non-adjusted
  ➢ Income and education were also big drivers

❖ Non-pharmacological
  ➢ Excluding psychotherapy, Asian patients were repeatedly more likely to receive Non-Pharmacological therapies.
  ➢ Asians were least likely to receive psychotherapy
For example: Gabapentin

<table>
<thead>
<tr>
<th></th>
<th>Partly Adjusted</th>
<th>P-value</th>
<th>Fully Adjusted</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Race (ref=Asian)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>0.118***</td>
<td>p&lt;0.001</td>
<td>0.0690***</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0.0846***</td>
<td>p&lt;0.001</td>
<td>0.0476***</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>White</td>
<td>0.0603***</td>
<td>p&lt;0.001</td>
<td>0.0446***</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td><strong>Income (ref=over 100K)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Under 40k</td>
<td></td>
<td></td>
<td>0.105***</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>40k to 100k</td>
<td></td>
<td></td>
<td>0.0420***</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Missing</td>
<td></td>
<td></td>
<td>0.0798***</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td><strong>Education (ref=college or more)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High school or less</td>
<td></td>
<td></td>
<td>0.0636***</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Some college</td>
<td></td>
<td></td>
<td>0.0288***</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Missing</td>
<td></td>
<td></td>
<td>0.0356***</td>
<td>p&lt;0.001</td>
</tr>
</tbody>
</table>
Policy must change.
Trends in Pharmacological Pain Care: 2010-2020

Gabapentin Alarm!
Trends in Non-Pharmacological Pain Care: 2010-2020

Hassle costs, SDOHs!
Misconceptions, MD Curriculums and Primary Care must change.

Misconceptions in literature about African Americans access to pain management drugs must change.

Medical school curriculums MUST change, to train doctors better.

Chronic pain may be like a “piedra en el zapato”: the role of primary care.
My role in the project / Lessons learned
Learned lots!

- CPT Codes expertise → extended it to other projects.
- Writing a manuscript.
- Leading a paper → Literature review → Present new findings → What does it take to write a paper?
- New interests → Pain → Opioid epidemic and other drugs - Colombia past → Future paths → CHIBE-PAIIR Retreat
- Publications!
Special thanks to these wonderful women, friends and mentors.
Income is a driver of pain management, thus, insurance claims angle gives value to both papers.

Non-opioid medications may be expensive.

Non-pharmacological treatments involve many hassle costs.

Underserved communities usually have lower incomes and healthcare access.

Better income is positively related to better education - health literacy.